Contineum Therapeutics Inc
NASDAQ:CTNM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Investment Trust of India Ltd
NSE:THEINVEST
|
IN |
|
B
|
Beijing Bashi Media Co Ltd
SSE:600386
|
CN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.6), the stock would be worth $-39.31 (403% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.8 | $12.96 |
0%
|
| Industry Average | 14.6 | $-39.31 |
-403%
|
| Country Average | 19.6 | $-52.67 |
-506%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Contineum Therapeutics Inc
NASDAQ:CTNM
|
483.7m USD | -4.8 | -8.5 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
303.9B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 537.2 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.7B ZAR | 14.4 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.1B USD | -18 026.5 | 38 496.8 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
61.5B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.8B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
33.1B EUR | 67.3 | 175.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
38.1B USD | -746.1 | -3 496.4 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.2B ZAR | 17.7 | 7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Contineum Therapeutics Inc
Glance View
Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
